Skip to main content
. 2007 Feb 3;16(8):1085–1100. doi: 10.1007/s00586-007-0308-z

Table 5.

Summary of BKP case series: efficacy results

N Mean (95% CI)* P value Heterogeneity P value
Change in pain (VAS 0–10 mm) 14 MD −5.4 mm (95% CI −6.3 to −4.4)* P < 0.0001 <0.0001
Change in functional capacity (different scales) 5 SMD 1.0 (0.6 to 1.5)* <0.0001 <0.0001
Change in quality of life (SF-36 0–100)
 Physical functioning 5 MD −21 (−28 to −14)* <0.0001 0.036
 Role physical 4 MD −31 (−42 to −20)* <0.0001 0.009
 Bodily pain 5 MD −29 (−38 to −19)* <0.0001 <0.0001
 General health 5 MD +4 (−2 to 10)* 0.266 0.013
 Vitality 5 MD −11 (−14 to −8) <0.0001 0.146
 Social functioning 5 MD −29 (−39 to −18)* <0.0001 0.001
 Role emotional 4 MD −18 (−39 to 4)* 0.109 <0.0001
 Mental health 5 MD −11 (−17 to −5)* <0.0001 0.008
Satisfaction at follow up (%) 2 MD 98 (90 to 100) <0.001 0.973
Change in vertebral height (% original height) 9 MD 21 (15 to 26)* <0.0001 <0.0001
Change in kyphotic angle (°) 12 MD −6.3 (−5.8 to −6.7) <0.0001 0.826

* Random effects model

MD mean difference, SMD standardised mean difference